IMRA News and Press, IMARA Inc. From 04/05/22

IMARA (IMRA) -40% as it plans to cull sickle cell/beta-thalassemia programs of tovinontrine after 2 trials disappoint. Cognyte Software (CGNT) -24% on Q4 earnings release GBS (GBS) -16%. Acer Therapeutics (ACER) -10%. Takung Art (TKAT) -8%. Precipio PRPO -7% on F...

Imara (NASDAQ:IMRA) said it will discontinue further development of tovinontrine (IMR-687) in sickle cell disease (SCD) and beta-thalassemia after the therapy failed to show benefit in two phase 2b trials. The Boston-based company is also discontinuing the two phase 2b studies ...

Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat population Interim results in Forte trial for beta-thalassemia demonstrated no mean...

Imara Inc. (IMRA) Q4 2021 Earnings Conference Call March 15, 2022 8:30 am ET Company Participants Rahul Ballal - President, Chief Executive Officer Mike Gray - Chief Financial Officer, Chief Operating Officer Ken Attie - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - C...

Imara press release (NASDAQ:IMRA): FY GAAP EPS of -$2.37 beats by $0.21. Cash, cash equivalents and investments of $90.28M. CEO comment: "We are pleased to have expanded our pipeline with the addition of IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2–related fac...

Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized r...

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the com...

Gainers: HOOKIPA Pharma HOOK +18%. Nuvectis Pharma (NASDAQ:NVCT) +16%. Ocugen OCGN +14%. Privia Health (NASDAQ:PRVA) +12%. IMARA (NASDAQ:IMRA) +11%. Losers: Allarity Therapeutics (NASDAQ:ALLR) -29%. Homology Medicines FIXX -27%. Karyopharm The...

Meritor (NYSE:MTOR) +43% Cummins acquires Meritor with eyes on electric power applications. Digital World Acquisition (NASDAQ:DWAC) +17% Trump's TRUTH Social platform hits Apple's App Store. Ocugen (NASDAQ:OCGN) +16% after FDA lifted hold on study for COVID-19 va...

There are many ways to find the best penny stocks to buy , including hunting for chart set-ups and looking for unusual trading activity. Others focus their strategy around finding top stocks under $1 or even below $0.50 that might be considered a good long shot investment opportunit...